Joint Nordic Procurement of Pharmaceuticals — 2020 — NF 1.621.b

AMGROS I/S

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award Framework Agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11).
Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).
The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.

Deadline

Fristen for modtagelse af bud var på 2019-05-21. Indkøbet blev offentliggjort på 2019-04-08.

Leverandører

Følgende leverandører er nævnt i tildelingsbeslutninger eller andre indkøbsdokumenter:

Hvem?

• AMGROS I/S

Hvad?

• Medicinsk udstyr, lægemidler og produkter til personlig pleje › Lægemidler

Hvor?

• Danmark › Danmark
• Norge
• Ísland

Indkøbshistorik

Dato	Dokument
2019-04-08	Udbudsbekendtgørelse
2019-04-26	Supplerende oplysninger
2019-08-12	Bekendtgørelse om indgåede kontrakter

Udbudsbekendtgørelse (2019-04-08)
Objekt
Omfanget af udbuddet
Titel: Lægemidler
Kort beskrivelse:

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award Framework Agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11). Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4). The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.

Bekendtgørelsens metadata
Originalsprog: engelsk 🗣️
Dokumenttype: Udbudsbekendtgørelse
Kontraktens art: Varer
Forordning: Den Europæiske Union, med deltagelse af GPA-lande
Fælles glossar for offentlige kontrakter (CPV)
Kode: Lægemidler 📦
Sted for udførelsen
NUTS-region: Danmark 🏙️

Procedure
Procedureform: Offentligt udbud
Bud-type: Indsendelse gældende for alle delaftaler
Kriterier for tildeling
Den laveste pris

Ordregivende myndighed
Identitet
Land: Danmark 🇩🇰
Type af ordregivende myndighed: Offentligretligt organ
Navn på ordregivende myndighed: Amgros I/S
Postadresse: Dampfærgevej 22
Postnummer: 2100
Postby: København Ø
Kontakt
Internetadresse: http://www.amgros.dk 🌏
E-mail: udbud@amgros.dk 📧
Telefon: +45 88713000 📞
Fax: +45 88713008 📠
URL til dokumenter: http://www.amgros.dk 🌏

Reference
Datoer
Afsendelsesdato: 2019-04-08 📅
Tilbudsfrist: 2019-05-21 📅
Offentliggørelsesdato: 2019-04-11 📅
Startdato: 2020-02-01 📅
Slutdato: 2021-01-31 📅
Identifikatorer
Bekendtgørelsesnummer: 2019/S 072-169900
EUT-S-nummer: 72
Yderligere oplysninger

The tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened collectively after expiry of the deadline for submission of tenders.

Objekt
Omfanget af udbuddet
Kort beskrivelse:

Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).

The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.

Anslået samlet værdi: 6 000 000 EUR 💰
Kort beskrivelse:

Procurement No: 1

ATC Code: J01DH02

Generic name: Meropenem (Vial)

Pharmaceutical form: Powder for infusionfluid

Strength: 500 mg

Unit value: 3 g

Volume in units: (Norway: 3750)(Denmark: 6695)(Iceland: 19)

Strength: 1 g

Volume in units: (Norway: 65500) (Denmark: 1784490) (Iceland: 495).

Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).

Anslået værdi uden moms: 6 000 000 EUR 💰
Beskrivelse af fornyelser:

The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.

Beskrivelse af mulighederne:

Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement the Framework Agreement will cover delivery of the pharmaceuticals in all three countries for the purchase period.

If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

Juridiske, økonomiske, finansielle og tekniske oplysninger
Betingelser for deltagelse
Egnethed til at udøve det erhverv:

Suppliers wishing to submit tender must use the standard form of the European Single Procurement Document (ESPD) for the declaration regarding the compulsory grounds for exclusion set out in Sections 135-136 of the Danish Public Procurement Act (udbudsloven) (Act No 1564 of 15.12.2015 as amended). Further information on the completion and application of the ESPD in the tender process is available in the guide drawn up by Amgros in this respect and in the “Instructions for the European Single Procurement Document” drawn up by the Danish Competition and Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s) to whom the Contracting Authorities intends to award the Framework Agreement must also, before the award, provide documentation to the Contracting Authorities regarding the absence of compulsory grounds for exclusion as set out in Sections 152-153 of the Public Procurement Act. The Contracting Authorities is not entitled to exclude a supplier who is subject to one or more of the mandatory exclusion grounds set out in Sections 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation that the supplier is reliable, even if the supplier is subject to 1 or more of the grounds for exclusion set out in Section 138 of the Public Procurement Act. The Contracting Authorities reserves the right to carry out a so-called “self-cleaning” process if relevant.

Økonomisk og finansiel stilling: No information required.
Teknisk og faglig kompetence: No information required.
Kontraktens udførelse
Betingelser for opfyldelse af kontrakten:

Reference is made to the provisions of the draft framework agreement and Section II.2.4).

No specific legal form is required. If the contract is awarded to a group of suppliers, each participant must undertake joint and several liability and appoint a joint representative.

Procedure
Retsgrundlag: 32014L0024
Gældende udbudslovgivning: Danish Law
Tidspunkt for modtagelse af tilbud: 12:00
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: dansk 🗣️
norsk 🗣️

+ 2 mere

svensk 🗣️
engelsk 🗣️

Dato for åbning af tilbud: 2019-05-21 📅
Tidspunkt for åbning af tilbud: 12:00
Sted: Amgros I/S, Dampfærgevej 27-29, DK-2100 Copenhagen Ø.
Yderligere oplysninger:

Ordregivende myndighed
Identitet
Navn på ordregivende myndighed: Landspítali
Postadresse: Eiríksgata 5
Postby: Reykjavík
Postnummer: 101
Land: Island 🇮🇸
Navn på ordregivende myndighed: Sykehusinnkjøp HF, divisjon legemidler
Postadresse: Grev Wedels plass 7
Postby: Oslo
Postnummer: 0151
Land: Norge 🇳🇴
Kontakt
Enhed: Flemming Sonne
Hulda Harðardóttir
E-mail: huldahar@landspitali.is 📧
Internetadresse: http://www.rikiskaup.is 🌏
Enhed: Eirik Sverrisson
E-mail: eirik.sverrisson@sykehusinnkjop.no 📧
Internetadresse: http://www.sykehusinnkjop.no 🌏
URL til dokumenter: www.amgros.dk 🌏
URL til dokumenter: www.amgros.dk 🌏

Reference
Yderligere oplysninger

In relation to Section II.2.4) it should be noted that the Contracting Authorities has considered whether the procurement group can be subdivided. The Contracting Authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals.

In relation to Sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in Section II.1.5) is the total estimated value of the procurement for the duration of the Framework Agreement, including the option of renewal, see Section II.2.7) and based on the AIP (“Apotekernes Indkøbspris” published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a Framework Agreement may differ significantly from the estimate, see Section II.2.4), Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.

Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.

The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.

In relation to Section VI.2) it should be noted that electronic invoicing is required.

Supplerende oplysninger
Gennemgå organ
Navn: Klagenævnet for Udbud
Postadresse: Nævnenes Hus, Toldboden 2
Postby: Viborg
Postnummer: 8800
Land: Danmark 🇩🇰
Telefon: +45 35291095 📞
E-mail: klfu@erst.dk 📧
Internetadresse: https://erhvervsstyrelsen.dk/klagenaevnet-for-udbud 🌏
Oplysninger om frister for klageprocedurer:

Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act No 593 of 2.6.2016 as amended) the following deadlines apply to the lodging of complaints:

Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within 6 months after the contracting entity has entered into a Framework Agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see Section 7(2), Para. (3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the Contracting Authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see Section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see Clause 6(4) of the Act.

Tjeneste, hvorfra der kan indhentes oplysninger om klageproceduren
Navn: Konkurrence- og Forbrugerstyrelsen
Postadresse: Carl Jacobsens vej 35
Postby: Valby
Postnummer: 2500
Telefon: +45 41715000 📞
Internetadresse: http://www.kfst.dk 🌏
Kilde: OJS 2019/S 072-169900 (2019-04-08)

Supplerende oplysninger (2019-04-26)
Objekt
Omfanget af udbuddet
Kort beskrivelse:

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award Framework Agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see section II.2.11. Tenders for the pharmaceuticals are invited so that the Contracting Authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (section II.2.4). The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.

Bekendtgørelsens metadata
Dokumenttype: Supplerende oplysninger

Reference
Datoer
Afsendelsesdato: 2019-04-26 📅
Offentliggørelsesdato: 2019-04-30 📅
Identifikatorer
Bekendtgørelsesnummer: 2019/S 084-200195
Henviser til bekendtgørelse: 2019/S 072-169900
EUT-S-nummer: 84

Objekt
Omfanget af udbuddet
Kort beskrivelse:

Tenders for the pharmaceuticals are invited so that the Contracting Authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (section II.2.4).

Kilde: OJS 2019/S 084-200195 (2019-04-26)

Bekendtgørelse om indgåede kontrakter (2019-08-12)
Objekt
Omfanget af udbuddet
Kort beskrivelse:

Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see section II.2.11). Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into framework agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (section II.2.4). The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.

Den samlede værdi af udbuddet: 5 990 000 EUR 💰
Bekendtgørelsens metadata
Dokumenttype: Bekendtgørelse om indgåede kontrakter

Procedure
Bud-type: Finder ikke anvendelse

Reference
Datoer
Afsendelsesdato: 2019-08-12 📅
Offentliggørelsesdato: 2019-08-14 📅
Identifikatorer
Bekendtgørelsesnummer: 2019/S 156-384844
EUT-S-nummer: 156
Yderligere oplysninger

This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see section VI.4). In relation to section II.2.4) it should be noted that the contracting authorities has considered whether the procurement group can be subdivided. The contracting authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals. In relation to sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in section II.1.5) is the total estimated value of the procurement for the duration of the framework agreement, including the option of renewal, see section II.2.7). and based on the AIP (‘Apotekernes Indkøbspris’ published by the Danish Medicines Agency) of the Parmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may differ significantly from the estimate, see section II.2.4), paragraph 3.6 of the tender specifications and clause 2 of the framework agreement. Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard. The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide. In relation to section VI.2) it should be noted that electronic invoicing is required.

Yderligere oplysninger

This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see section VI.4).

In relation to section II.2.4) it should be noted that the contracting authorities has considered whether the procurement group can be subdivided. The contracting authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals.

In relation to sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in section II.1.5) is the total estimated value of the procurement for the duration of the framework agreement, including the option of renewal, see section II.2.7). and based on the AIP (‘Apotekernes Indkøbspris’ published by the Danish Medicines Agency) of the Parmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may differ significantly from the estimate, see section II.2.4), paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.

Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.

The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.

In relation to section VI.2) it should be noted that electronic invoicing is required.

Objekt
Omfanget af udbuddet
Kort beskrivelse:

Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into framework agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (section II.2.4).

The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the framework agreement.

Procurement No 1

Volume in units: (Norway:65500)(Denmark:1784490)(Iceland:495)

Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.

It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.

Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see section II.2.11).

Beskrivelse af mulighederne:

Clause 1 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the framework agreement and in the tender specifications.

For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a framework agreement the framework agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.

If the supplier chooses not to give a tender for the delivery to Iceland the framework agreement will cover delivery of the pharmaceuticals in Denmark and Norway.

Procedure
Gældende udbudslovgivning: Danish law.

Tildeling af kontrakt
Dato for kontraktindgåelse: 2019-08-08 📅
Navn: Sun Pharmaceutical Germany GmbH
Postby: Leverkusen
Land: Tyskland 🇩🇪
Navn: FrostPharma AB
Postby: Danderyd
Land: Sverige 🇸🇪
Navn: Fresenius Kabi
Postby: København
Land: Danmark 🇩🇰
Hovedstaden 🏙️
Den samlede værdi af udbuddet: 5 989 351 EUR 💰
Oplysninger om udbud
Antal modtagne bud: 3

Reference
Yderligere oplysninger

In relation to section II.2.4) it should be noted that the contracting authorities has considered whether the procurement group can be subdivided. The contracting authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals.

In relation to sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in section II.1.5) is the total estimated value of the procurement for the duration of the framework agreement, including the option of renewal, see section II.2.7). and based on the AIP (‘Apotekernes Indkøbspris’ published by the Danish Medicines Agency) of the Parmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may differ significantly from the estimate, see section II.2.4), paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.

In relation to section VI.2) it should be noted that electronic invoicing is required.

Supplerende oplysninger
Gennemgå organ
Oplysninger om frister for klageprocedurer:

Complaints of the tendering procedure must be lodged with the complaints board for public procurement within 6 months after the contracting entity has entered into a framework agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see section 7(2), para.(3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.

Kilde: OJS 2019/S 156-384844 (2019-08-12)

Nye indkøb inden for beslægtede kategorier 🆕

Medicinsk udstyr, lægemidler og produkter til personlig pleje (>20 nye indkøb)

Lægemidler (>20)